SME
Description
A differentiated platform therapeutics company approaching a major value inflection point.
Proprietary Platform:
A³SMO® is a proprietary oral peptide delivery platform designed to enable systemic delivery of therapeutic peptides, creating the foundation for multiple product opportunities from a single technology platform.
Pipeline with Repeatable Value Creation:
The platform has already generated a lead development candidate (LDN-0712), a second preclinical programme (LDN-603), and a growing portfolio of discovery-stage assets, demonstrating its potential to produce multiple therapeutic products rather than a single asset.
Attractive Timing:
The Company is approaching IND-enabling development, representing a significant value inflection before first-in-human clinical studies while maintaining substantial upside for new investors.
Institutional Validation:
A Letter of Intent from a Capital Fund provides institutional validation of the Company’s strategy and supports completion of the current financing round through syndication with additional investors.
Scalable Business Model
Ladon combines internal product development with future partnering and licensing opportunities, creating multiple potential paths for long-term value creation.
Building a platform company capable of generating multiple orally delivered peptide therapeutics from a single proprietary technology.
